Joseph Luizzi
Lawyers
Filters
Expedia $1 billion convertible senior notes offering
The Rule 144A offering involved 0% convertible notes due 2026
Sunrun $400 million convertible senior notes offering
We advised the initial purchasers on the Rule 144A offering
NextEra Energy Partners $600 million convertible senior notes offering
Davis Polk acted as special product counsel to the initial purchaser in connection with a Rule 144A offering by NextEra Energy Partners, LP of an aggregate principal amount of $600 million…
GoPro $143.75 million convertible senior notes offering
Davis Polk advised the representative of the initial purchasers in a Rule 144A offering by GoPro, Inc. of $143.75 million aggregate principal amount of 1.250% convertible senior notes due…
Medallia $575 million convertible notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Medallia, Inc. of $575 million aggregate principal amount of its 0.125%…
Etsy $650 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Etsy, Inc. of $650 million aggregate principal amount of its 0.125% convertible senior notes due…
PG&E $16 billion equity and debt exit offerings
Davis Polk advised the representatives of the several underwriters in connection with concurrent SEC-registered offerings by PG&E Corporation (“PG&E”) of 423,372,629 shares of…
Sea $1.15 billion convertible senior notes offering
Davis Polk advised the initial purchaser in connection with a Rule 144A and Regulation S offering by Sea Limited of $1.15 billion aggregate principal amount of its 2.375% convertible…
Enphase Energy $320 million convertible notes offering
Davis Polk advised the joint book-running managers in connection with a Rule 144A offering by Enphase Energy, Inc. of $320 million aggregate principal amount of its 0.25% convertible senior…
Revance Therapeutics $287.5 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Revance Therapeutics, Inc. of $287.5 million aggregate principal amount of its 1.75% convertible senior…